Abstract
Mushrooms have been consumed for their health benefits for thousands of years in China, and the main active component was recently identified as beta-glucan. The immune-stimulating effect of beta-glucans has been well studied, and several beta-glucan receptors have been identified on the surface of immune cells. In addition, mushroom extracts with high levels of beta-glucans have also been shown to have direct cytotoxic effects on cancer cells, and beta-glucans are used for the treatment of cancer. This review summarizes the use of beta-glucans in colon cancer. Evidence has supported the idea that beta-glucans can decrease the size of xenografted colon cancer tumors via the stimulation of the immune system and direct cytotoxicity. Beta-glucans can also have synergistic effects with chemotherapeutic agents and other immune stimulators, and an innovative strategy is to use beta-glucans to deliver nanoparticles containing chemotherapeutic agents to the site of the colon cancer and, thus, improve the therapeutic efficacy.
Keywords: Beta-glucans, macrophages, dendritic cells, cytotoxicity, nanoparticles.
Anti-Cancer Agents in Medicinal Chemistry
Title:The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Volume: 13 Issue: 5
Author(s): Jiezhong Chen, Xu Dong Zhang and Zhengyi Jiang
Affiliation:
Keywords: Beta-glucans, macrophages, dendritic cells, cytotoxicity, nanoparticles.
Abstract: Mushrooms have been consumed for their health benefits for thousands of years in China, and the main active component was recently identified as beta-glucan. The immune-stimulating effect of beta-glucans has been well studied, and several beta-glucan receptors have been identified on the surface of immune cells. In addition, mushroom extracts with high levels of beta-glucans have also been shown to have direct cytotoxic effects on cancer cells, and beta-glucans are used for the treatment of cancer. This review summarizes the use of beta-glucans in colon cancer. Evidence has supported the idea that beta-glucans can decrease the size of xenografted colon cancer tumors via the stimulation of the immune system and direct cytotoxicity. Beta-glucans can also have synergistic effects with chemotherapeutic agents and other immune stimulators, and an innovative strategy is to use beta-glucans to deliver nanoparticles containing chemotherapeutic agents to the site of the colon cancer and, thus, improve the therapeutic efficacy.
Export Options
About this article
Cite this article as:
Chen Jiezhong, Zhang Xu Dong and Jiang Zhengyi, The Application of Fungal Beta-glucans for the Treatment of Colon Cancer, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (5) . https://dx.doi.org/10.2174/1871520611313050007
DOI https://dx.doi.org/10.2174/1871520611313050007 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medicinal Plants for the Prevention and Treatment of Bacterial Infections
Current Pharmaceutical Design Prediction of Tetralogy of Fallot using Fuzzy Clustering
Recent Advances in Computer Science and Communications Progress in Detection of Insomnia Sleep Disorder: A Comprehensive Review
Current Drug Targets Impact of Matrix Metalloproteinases on Atherosclerosis
Current Drug Targets Q Fever Endocarditis
Infectious Disorders - Drug Targets Magnesium and Anaesthesia
Current Drug Targets Carotid Intima Media Thickness and Beyond
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial [Hot Topic: Cardiovascular Diagnostic Testing: Use and Limits of Biochemical Markers (Executive Editors: Aurelio Leone and Stefano Taddei)]
Current Pharmaceutical Design Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Impact of Chronic Kidney Disease on Risk for Vascular Events
Current Vascular Pharmacology Sex Hormones, Metabolic Syndrome and Kidney
Current Topics in Medicinal Chemistry Editorial (Thematic Issues: Autoimmunity and Autoinflammation: Cardiovascular Drug Targets and Design)
Current Pharmaceutical Design Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits
Cardiovascular & Hematological Disorders-Drug Targets T Cell Homeostasis in Centenarians: From the Thymus to the Periphery
Current Pharmaceutical Design Copper as a Biocidal Tool
Current Medicinal Chemistry Polypharmacology in a Single Drug: Multitarget Drugs
Current Medicinal Chemistry Atrial Fibrillation Following Cardiac Surgery: Established and Emerging Strategies of Prevention
Recent Patents on Cardiovascular Drug Discovery Patents on Metallic Biodegradable Stents
Recent Patents on Materials Science Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacokinetic-Pharmacodynamic Modeling of Antihypertensive Drugs: From Basic Research to Clinical Practice
Current Hypertension Reviews